|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Blepharitis |
|
Blepharoconjunctivitis |
|
Burns |
|
Conjunctivitis, infectious |
|
Dacryocystitis |
|
Infection, bone |
|
Infection, central nervous system |
|
Infection, gastrointestinal tract |
|
Infection, intra- abdominal |
|
Infection, ophthalmic |
|
Infection, respiratory tract |
|
Infection, skin and skin structure |
|
Infection, urinary tract |
|
Keratitis |
|
Keratoconjunctivitis |
|
Meibomianitis |
|
Meningitis |
|
Peritonitis |
|
Septicemia |
|
Ulcer, corneal |
| |
|
|
SIDE EFFECTS:
|
|
azotemia |
|
cylindruria |
|
dizziness |
|
hearing loss |
|
hyposthenuria |
|
injection site reaction |
|
interstitial nephritis |
|
myasthenia |
|
proteinuria |
|
pseudotumor cerebri |
|
pyuria |
|
renal tubular acidosis |
|
tinnitus |
|
vertigo |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
botulism |
|
breast-feeding |
|
dehydration |
|
elderly |
|
Fabry disease |
|
hearing impairment |
|
myasthenia gravis |
|
neonates |
|
parkinsonism |
|
pregnancy |
|
renal disease |
|
|
ADULT DOSE:
|
|
Antibacterial(systemic) -Intramuscular or intravenous infusion, 1 to 1.7 mg (base) per kg of body weight every eight hours for seven to ten days or more.
Note: Urinary tract infections, bacterial (uncomplicated)-Intramuscular or intravenous infusion:
Adults less than 60 kg of body weight-3 mg(base) per kg of body weight once a day; or 1.5 mg per kg of body weight every twelve hours.
Adults 60 kg of body weight and over-160 mg(base) once a day; or 80 mg every twelve hours.
Following hemodialysis, a supplemental dose of 1 to 1.7 mg (base) per kg of body weight may be administered, depending on the severity of the infection.
Intralumbar or intraventricular, 4 to 8 mg (base) once a day. |
|
MAXIMUM ADULT DOSE:
|
|
Up to 8 mg (base) per kg of body weight daily in severe, life-threatening infections.
Note: Doses up to 15 mg (base) per kg of body weight daily have been used in the treatment of intraocular infections.
|
|
PEDIATRIC DOSE:
|
|
Antibacterial(systemic)-Intramuscular or intravenous infusion- Premature or full-term neonates up to 1 week of age:
2.5 mg (base) per kg of body weight every twelve to twenty-four hours for seven to ten days or more.
Older neonates and infants:
2.5 mg (base) per kg of body weight every eight to sixteen hours for seven to ten days or more.
Children:
2 to 2.5 mg (base) per kg of body weight every eight hours for seven to ten days or more.
Note:
The dosing interval of gentamicin in pediatric patients may vary from every four hours to every twenty-four hours, depending on the medical condition of the patient (cystic fibrosis, burns, renal dysfunction); serum levels must be monitored.
Following hemodialysis, a supplemental dose of 2 to 2.5 mg (base) per kg of body weight may be administered, depending on the severity of the infection.
Intralumbar or intraventricular- Infants up to 3 months of age:
Dosage has not been established.
Infants and children 3 months of age and over:
1 to 2 mg (base) once a day.
Note:
Doses up to 8 mg (base) daily have been used in infants with functioning ventricular shunts. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|